REG - AstraZeneca PLC - Notice of AGM

AstraZenecaAnnouncement

23/03/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW6591Fa&default-theme=true

RNS Number : 6591F  AstraZeneca PLC  23 March 2022

23 March 2022 11:00 GMT

 

Notice of Annual General Meeting

 

AstraZeneca PLC (the Company) announced today the publication of its Notice of
Annual General Meeting 2022 and Shareholders' Circular (the Notice).

 

The Notice and the proxy form for the Annual General Meeting (AGM) have been
submitted to the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . The Notice is also
available on the Company's website at www.astrazeneca.com/noticeofmeeting2022.

 

The Company's Annual Report and Form 20-F Information 2021 (the Annual Report)
was published on 22 February 2022.

 

The Notice is being despatched to shareholders today.

 

The meeting place for the AGM will be the Royal Lancaster London Hotel,
Lancaster Terrace, London W2 2TY and the AGM will commence at 2.30 pm (BST) on
29 April 2022.

 

At the time of issuing the Notice, there are no restrictions in the UK
relating to COVID-19 that would prevent the AGM going ahead or significantly
affect the arrangements for the meeting. If circumstances change before the
date of the AGM, the Board may be required or may decide to alter the
arrangements for the meeting to ensure the health and safety of those present
at the meeting. Any alterations to the arrangements will be advertised on the
Company's website, www.astrazeneca.com (http://www.astrazeneca.com) , and
where appropriate by stock exchange announcement.

 

The business to be conducted at the AGM is summarised below:

1.   To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December 2021

2.   To confirm dividends

3.   To reappoint PricewaterhouseCoopers LLP as Auditor

4.   To authorise the Directors to agree the remuneration of the Auditor

5.   To elect or re-elect Directors

6.   To approve the Annual Report on Remuneration for the year ended 31
December 2021

7.   To authorise limited political donations

8.   To authorise the Directors to allot shares

9.   To authorise the Directors to disapply pre-emption rights

10. To authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments

11. To authorise the Company to purchase its own shares

12. To reduce the notice period for general meetings

13. To extend the AstraZeneca 2012 Savings Related Share Option Scheme

 

Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001,
only holders of ordinary shares entered in the register of members of the
Company by 6.30pm (BST) on 27 April 2022 (or their duly appointed proxies), or
if this meeting is adjourned, in the register of members by 6.30pm (BST) two
days prior to any adjourned meeting, are entitled to attend or vote at the AGM
in respect of the number of ordinary shares registered in their name at that
time. Changes to the entries in the register of members after 6.30pm (BST) on
27 April 2022, or if this meeting is adjourned, in the register of members
after 6.30pm (BST) two days prior to any adjourned meeting, shall be
disregarded in determining the rights of any person to attend or vote at the
AGM. The Record Date applied to the Euroclear Sweden system to determine
entitlement to attend and vote at the AGM is close of business on 19 April
2022.

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/)  and
follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca)
.

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPPUPAWUPPGQP